Impact of anemia on short‐term outcomes after <scp>TAVR</scp>: A subgroup analysis from the <scp>BRAVO</scp>‐3 randomized trialVictor Razuk, George Dangas, Frans Beerkens et al.|Catheterization and Cardiovascular Interventions|2021Cited by 4
IMPACT OF CORONARY ARTERY DISEASE ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIALDaniel Feldman, George Dangas, Davide Cao et al.|Journal of the American College of Cardiology|2022Cited by 2
Impact of Chronic Kidney Disease on Periprocedural Anticoagulation and Short-Term Outcomes after TAVR: A BRAVO-3 Trial SubanalysisVictor Razuk, George Dangas, Davide Cao et al.|SSRN Electronic Journal|2021Cited by 0
IMPACT OF CHRONIC THROMBOCYTOPENIA ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIALDaniel Feldman, George Dangas, Davide Cao et al.|Journal of the American College of Cardiology|2022Cited by 0